Leading Taiwan-Based Biotech Company Signs Pristima® Software Subscription Agreement with Xybion Corporation

Xybion Corporation, a US-based global technology solutions provider for companies operating in the highly regulated industries, announced today that Level Biotechnology Inc., a leading Taiwan-based biotechnology company, has signed a software subscription agreement for Pristima, Xybion’s flagship pre-clinical solution, and Savante™, its popular module for production of FDA compliant SEND submissions.

Xybion Corporation, a US-based global technology solutions provider for companies operating in the highly regulated industries, announced today that Level Biotechnology Inc., a leading Taiwan-based biotechnology company, has signed a software subscription agreement for Pristima, Xybion’s flagship pre-clinical solution, and Savante™, its popular module for production of FDA compliant SEND submissions.

This agreement follows an extensive analysis of all competitors in the preclinical space and allows Level Biotechnology Inc. to leverage Pristima’s core components, such as Clinical Pathology, Animal Room, Necropsy Room, and Histopathology to support its pre-clinical laboratory services.

Xybion will be providing Pristima Software-as-a-Service (SaaS) solution, utilizing hosted (private cloud) services from its Singapore data center. Importantly, Pristima will be interfaced to support real-time communications with clinical pathology instruments at Level Biotechnology. “Level Biotechnology was looking for a comprehensive integrated SaaS solution, which would help us push compliance across our business functions and allow us to optimize our pre-clinical operations,” stated Emerson Chiu, President of Level Biotechnology. “We went through a rigorous search for the best solution and we felt that Xybion’s partnership and their industry leading Pristima software platform is the right fit for our organization.”

Expressing confidence in this partnership, Carlos Frade, Vice President of Preclinical R&D Solutions at Xybion said, “We are excited about being selected by Level Biotechnology for our pre-clinical suite. I am confident in Xybion’s decades of expertise in the pre-clinical market and certain that deployment of our Pristima and Savante solutions will immediately benefit Level Biotechnology’s efficiency, productivity and reporting timelines.”

Xybion’s Chief Executive Officer, Dr. Pradip Banerjee went on to say “At Xybion, we strive to earn the trust and support of our clients and create a lasting position of valued partner.” Dr. Banerjee continued, “We see Xybion’s footprint and reputation expanding globally and seek to set an industry benchmark in the APAC market. We look forward to a long-term business relationship with Level Biotechnology.”

About Xybion Corporation
Xybion is the leading provider of software, services and consulting for global corporations operating in highly regulated industries. Our unique solutions focus on regulatory compliance, GRC, quality management, GLP, integrated preclinical lab management, early-stage drug discovery, content migration and systems validation. Xybion specializes in helping companies improve their overall compliance processes and provides a complete view into organizational risk across global organizational models.

Xybion’s combination of software, business process management, services, validation, and staffing enables us to cover a broad spectrum of critical business needs for companies and we deliver our solutions on a global scale. Since its founding in 1977, Xybion Corporation has supported, through software, services and consulting, 100% of the top 20 global life sciences companies. Our leadership in this dynamic and ever-changing industry has been a cornerstone of our high-value reputation.

About Level Biotechnology Inc.,
Founded in 1989, Level Biotechnology Inc. has been providing the best pre-clinical CRO services and end-to-end solution for biomedical research and drug development in Taiwan. Apparently, its CRO services support more than 9,900 square yards of laboratory space.